Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS clinical trials group A5211

Zhaohui Su; Roy M. Gulick; Amy Krambrink; Eoin Coakley; Michael D. Hughes; Dong Han; Charles Flexner; Timothy J. Wilkin; Paul R. Skolnik; Wayne L. Greaves; Daniel R. Kuritzkes; Jacqueline D. Reeves

doi:10.1086/648090

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS clinical trials group A5211

Zhaohui Su, Roy M. Gulick, Amy Krambrink, Eoin Coakley, Michael D. Hughes, Dong Han, Charles Flexner, Timothy J. Wilkin, Paul R. Skolnik, Wayne L. Greaves, Daniel R. Kuritzkes, Jacqueline D. Reeves

School of Medicine

Research output: Contribution to journal › Article

Abstract

The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AIDS Clinical Trials Group A5211 who had CCR5-tropic (R5) virus detected by the original Trofile assay at study screening. Among 90 recipients of vicriviroc, a significantly (P < .001) greater mean reduction in HIV-1 RNA was observed in 72 subjects with R5 virus versus 15 subjects reclassified as having dual/mixed-tropic viruses at screening: -1.11 versus -0.09 log₁₀ copies/μL at day 14 and -1.91 versus -0.57 log₁₀ copies/μL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy.

Original language	English (US)
Pages (from-to)	1724-1728
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	200
Issue number	11
DOIs	https://doi.org/10.1086/648090
State	Published - Nov 2009

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1086/648090

Fingerprint Dive into the research topics of 'Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS clinical trials group A5211'. Together they form a unique fingerprint.

Cite this

Su, Z., Gulick, R. M., Krambrink, A., Coakley, E., Hughes, M. D., Han, D., Flexner, C., Wilkin, T. J., Skolnik, P. R., Greaves, W. L., Kuritzkes, D. R., & Reeves, J. D. (2009). Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS clinical trials group A5211. Journal of Infectious Diseases, 200(11), 1724-1728. https://doi.org/10.1086/648090

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay : Reanalysis of AIDS clinical trials group A5211. / Su, Zhaohui; Gulick, Roy M.; Krambrink, Amy; Coakley, Eoin; Hughes, Michael D.; Han, Dong; Flexner, Charles; Wilkin, Timothy J.; Skolnik, Paul R.; Greaves, Wayne L.; Kuritzkes, Daniel R.; Reeves, Jacqueline D.

In: Journal of Infectious Diseases, Vol. 200, No. 11, 11.2009, p. 1724-1728.

Research output: Contribution to journal › Article

Su, Z, Gulick, RM, Krambrink, A, Coakley, E, Hughes, MD, Han, D, Flexner, C, Wilkin, TJ, Skolnik, PR, Greaves, WL, Kuritzkes, DR & Reeves, JD 2009, 'Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS clinical trials group A5211', Journal of Infectious Diseases, vol. 200, no. 11, pp. 1724-1728. https://doi.org/10.1086/648090

Su, Zhaohui ; Gulick, Roy M. ; Krambrink, Amy ; Coakley, Eoin ; Hughes, Michael D. ; Han, Dong ; Flexner, Charles ; Wilkin, Timothy J. ; Skolnik, Paul R. ; Greaves, Wayne L. ; Kuritzkes, Daniel R. ; Reeves, Jacqueline D. / Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay : Reanalysis of AIDS clinical trials group A5211. In: Journal of Infectious Diseases. 2009 ; Vol. 200, No. 11. pp. 1724-1728.

@article{0c6acb83ad0d497fadb24979b985b048,

title = "Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS clinical trials group A5211",

abstract = "The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AIDS Clinical Trials Group A5211 who had CCR5-tropic (R5) virus detected by the original Trofile assay at study screening. Among 90 recipients of vicriviroc, a significantly (P < .001) greater mean reduction in HIV-1 RNA was observed in 72 subjects with R5 virus versus 15 subjects reclassified as having dual/mixed-tropic viruses at screening: -1.11 versus -0.09 log10 copies/μL at day 14 and -1.91 versus -0.57 log10 copies/μL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy.",

author = "Zhaohui Su and Gulick, {Roy M.} and Amy Krambrink and Eoin Coakley and Hughes, {Michael D.} and Dong Han and Charles Flexner and Wilkin, {Timothy J.} and Skolnik, {Paul R.} and Greaves, {Wayne L.} and Kuritzkes, {Daniel R.} and Reeves, {Jacqueline D.}",

year = "2009",

month = nov,

doi = "10.1086/648090",

language = "English (US)",

volume = "200",

pages = "1724--1728",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay

T2 - Reanalysis of AIDS clinical trials group A5211

AU - Su, Zhaohui

AU - Gulick, Roy M.

AU - Krambrink, Amy

AU - Coakley, Eoin

AU - Hughes, Michael D.

AU - Han, Dong

AU - Flexner, Charles

AU - Wilkin, Timothy J.

AU - Skolnik, Paul R.

AU - Greaves, Wayne L.

AU - Kuritzkes, Daniel R.

AU - Reeves, Jacqueline D.

PY - 2009/11

Y1 - 2009/11

N2 - The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AIDS Clinical Trials Group A5211 who had CCR5-tropic (R5) virus detected by the original Trofile assay at study screening. Among 90 recipients of vicriviroc, a significantly (P < .001) greater mean reduction in HIV-1 RNA was observed in 72 subjects with R5 virus versus 15 subjects reclassified as having dual/mixed-tropic viruses at screening: -1.11 versus -0.09 log10 copies/μL at day 14 and -1.91 versus -0.57 log10 copies/μL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy.

AB - The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AIDS Clinical Trials Group A5211 who had CCR5-tropic (R5) virus detected by the original Trofile assay at study screening. Among 90 recipients of vicriviroc, a significantly (P < .001) greater mean reduction in HIV-1 RNA was observed in 72 subjects with R5 virus versus 15 subjects reclassified as having dual/mixed-tropic viruses at screening: -1.11 versus -0.09 log10 copies/μL at day 14 and -1.91 versus -0.57 log10 copies/μL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy.

UR - http://www.scopus.com/inward/record.url?scp=70350179577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350179577&partnerID=8YFLogxK

U2 - 10.1086/648090

DO - 10.1086/648090

M3 - Article

C2 - 19874179

AN - SCOPUS:70350179577

VL - 200

SP - 1724

EP - 1728

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 11

ER -